Chemoembolization Agents for Loading Hydrophobic Cancer Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemoembolization agents are limited to drugs that can be loaded on commercially available embolic materials, primarily due to the requirement of charge and water solubility, excluding effective anti-cancer agents like Sorafenib, which are poorly water soluble and uncharged, leading to inadequate treatment options for solid vascularized tumors.
Innovation Solution
Development of chemoembolization agents that utilize embolizing particles or microspheres with encapsulating agents, such as cationic or anionic liposomes and cyclodextrins, to non-covalently attach uncharged or poorly water-soluble anti-cancer agents like Sorafenib, Regorafenib, Lenvatinib, and Sunitinib, enabling localized delivery to tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If commercially available embolic materials are used for chemoembolization, then the embolization effect is achieved, but the drug loading capability is limited to charged and water-soluble drugs only
Solution Approach 1:
The patent introduces an intermediary component (amphiphilic polymer or liposome) that mediates between the embolic material and the hydrophobic drug. This intermediary has both hydrophobic regions to bind the drug and hydrophilic regions to interact with the aqueous environment, enabling drug loading on embolic materials without requiring the drug to be charged or water-soluble.
Solution Approach 2:
The patent creates composite structures combining embolic materials with amphiphilic polymers or liposomes. These composite materials integrate the embolization function of the base material with the drug-carrying capacity of the amphiphilic component, expanding the range of loadable drugs to include hydrophobic and uncharged compounds.
2Quantity of substance
If high concentration of anti-cancer drug is delivered to tumor site, then treatment effectiveness is improved, but systemic side effects increase
Solution Approach 1:
The patent applies local quality by concentrating the drug delivery function specifically at the tumor site through embolization. The embolic material blocks blood flow locally, trapping the drug carrier (amphiphilic polymer or liposome) and its cargo within the tumor vasculature, creating high local drug concentration while minimizing systemic distribution.
Solution Approach 2:
The patent extracts the drug from the systemic circulation by using the embolic material to trap and retain the drug carrier within the tumor. This separation of drug delivery location from systemic circulation prevents the drug from reaching other organs and causing side effects.
3Reliability
If uncharged and poorly water-soluble drugs like Sorafenib are used, then treatment effectiveness for solid tumors is improved, but compatibility with conventional embolic materials is poor
Solution Approach 1:
The patent changes the physical-chemical parameters of the drug delivery system by using amphiphilic polymers and liposomes that can solubilize hydrophobic drugs through their micelle-forming or vesicle-encapsulating properties. This parameter change enables uncharged, poorly water-soluble drugs like Sorafenib to be delivered effectively through embolization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the effectiveness of anti-cancer drugs by achieving high concentrations at tumor sites while minimizing systemic side effects, effectively treating solid vascularized tumors including liver and kidney cancers.
Implementation Method 1
the encapsulating agent being a liposome, and a therapeutic agent contained within the encapsulating agent, the therapeutic agent being uncharged or weakly charged or the therapeutic agent having low solubility in aqueous media
Implementation Method 2
the encapsulating agent affixed to or attached to the embolizing particle or microsphere through ionic or other non-covalent interactions
Data Source
AI summary
Described herein is a chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug, as described herein.